Excellence Awards 2022 – Winners Announced!
Pharmaceutical Technology
DECEMBER 22, 2022
The main focus is the antibody-drug conjugate (ADC ), Enhertu (trastuzumab deruxtecan), which had already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma. appeared first on Pharmaceutical Technology.
Let's personalize your content